This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

  • Clinicaltrials.gov identifier

    NCT03850067

  • Recruitment Status

    Recruiting

  • First Posted

    February 21, 2019

  • Last update posted

    March 2, 2021

Study Description

Brief summary:

CC-90011-SCLC-001 is a multicenter, Phase 1b, open-label, dose finding study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently and sequentially to standard of care platinum-based, cisplatin and etoposide, carboplatin and etoposide and/or etoposide and Nivolumab to subjects with first line ES SCLC. The dose finding part of the study will explore escalating oral doses of CC-90011 in combination with cisplatin, etoposide and/or carboplatin with or without Nivolumab (chemotherapy), to determine the maximum tolerated dose of CC- 90011 in combination with chemotherapy with or without Nivolumab to subjects with first line ES SCLC.

  • Condition or Disease:Small Cell Lung Carcinoma
  • Intervention/Treatment: Drug: CC-90011
    Drug: Cisplatin
    Drug: Carboplatin
    Drug: Etoposide
    Drug: Nivolumab
  • Phase: Phase 1/Phase 2

Detailed Description

N/A

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 90 participants
  • Allocation: Non-Randomized
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase 1b, Multicenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of CC-90011 Given in Combination With Cisplatin and Etoposide in First -Line, Extensive Stage Subjects With Small Cell Lung Cancer
  • Actual Study Start Date: March 2019
  • Estimated Primary Completion Date: September 2021
  • Estimated Study Completion Date: April 2023

Arms and interventions

Arm Intervention/treatment
Experimental: CC-90011 in combination with Cisplatin and Etoposide
During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.
Drug: CC-90011
CC-90011

Drug: Cisplatin
Cisplatin
Experimental: CC-90011 in combination with Carboplatin and Etoposide
During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated
Drug: Carboplatin
Carboplatin

Drug: Etoposide
Etoposide
Experimental: Nivolumab combination
When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab (Nivo) IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and Nivo, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy. For subjects responding to the initial combination of CC-90011 and chemotherapy, as per RECIST 1.1, CC-90011 single agent will be given as maintenance therapy. These subjects will receive 60 mg of CC-90011 orally once weekly, Days 1, 8, 15, and 22, during cycles of 28 days each. For subjects responding to the initial combination of CC-90011 and chemotherapy with Nivo, CC-90011 with Nivo will be given as maintenance therapy. These subjects will receive 60 mg of CC-90011 orally once weekly, Days 1, 8, 15, and 22, and Nivo IV 240 mg Days 1 and 15 during cycles of 28 days each
Drug: Nivolumab
Nivolumab

Outcome Measures

  • Primary Outcome Measures: 1. Dose-Limiting Toxicity (DLT) [ Time Frame: Up to approximately 2 years ]
    A DLT is defined as any of the toxicities described in the protocol occurring within the DLT assessment unless the event can clearly be determined to be unrelated to CC-90011
  • 2. Maximum Tolerated Dose (MTD) [ Time Frame: Up to approximately 2 years ]
    MTD is the highest dose that causes DLTs in not more than 33% of the subjects treated with CC-90010 in the first cycle with at least 6 evaluable subjects treated at this dose
  • 3. Adverse Events (AEs) [ Time Frame: Up to approximately 3 years ]
    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE
  • Secondary Outcome Measures: 1. Objective Response Rate (ORR) [ Time Frame: Up to approximately 2 years ]
    Is defined as the percent of subjects whose best response is complete response (CR) or partial response (PR).
  • 2. Progression-free Survival (PFS) [ Time Frame: Up to approximately 2 years ]
    Is defined as the time from the first dose of study drug to the first occurrence of disease progression or death from any cause.
  • 3. Overall Survival (OS) [ Time Frame: Up to approximately 2 years ]
    Is measured as the time from the first dose of CC-90011 to death due to any cause.
  • 4. Pharmacokinetics- Cmax [ Time Frame: Up to approximately 2 years ]
    Maximum observed plasma concentration
  • 5. Pharmacokinetics- AUC [ Time Frame: Up to approximately 2 years ]
    Area under the plasma concentration time-curve
  • 6. Pharmacokinetics- Tmax [ Time Frame: Up to approximately 2 years ]
    Time to maximum plasma concentration
  • 7. Pharmacokinetics- t1/2 [ Time Frame: Up to approximately 2 years ]
    Terminal half-life
  • 8. Pharmacokinetics- CL/F [ Time Frame: Up to approximately 2 years ]
    Apparent clearance
  • 9. Pharmacokinetics- VzF [ Time Frame: Up to approximately 2 years ]
    Apparent volume of distribution

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male and female subject is 18 years of age or older at the time of signing the
informed consent form (ICF).

2. Subject with histological or cytological confirmation of extensive stage SCLC
according to 2015 WHO classification (Travis, 2015).

3. Subject must be able to provide fresh or archival tumor tissues

4. Subject is found suitable for at least 4 cycles of platinum-based standard
chemotherapy.

5. Subject has at least 1 site of measurable disease per RECIST 1.1.

6. Subject must have the following laboratory values:

- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

- Hemoglobin (Hgb) ≥ 10 g/dL (≥ 100 g/L or > 6.2 mmol/L)

- Platelet count (Plt) ≥ 150 x 109/L

- Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase
(AST/SGOT) and alanine aminotransferase/serum glutamate pyruvate transaminase
(ALT/SGPT) ≤ 3.0 x upper limit of normal (ULN) or ≤ 5.0 x ULN if liver metastases
are present

- Serum total bilirubin ≤ 1.5 x ULN

- Serum albumin ≥ 3.0 g/dL

- Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min (see Appendix G
to see creatinine clearance formula). For the purposes of this protocol, the
glomerular filtration rate (GFR) is considered to be equivalent to the creatinine
clearance.

- Prothrombin time (or international normalized ratio [INR]) and activated partial
thromboplastin time (APTT) ≤ 1.5 ULN

Exclusion Criteria:

1. Subject has received anticancer therapy (either approved or investigational, including
radiation with curative intent) for SCLC prior to study entry.

2. Subject has undergone major surgery ≤ 4 weeks prior to Cycle 1 Day 1 or has not
recovered from surgery.

3. Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue
or inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management), or
any other significant gastrointestinal (GI) disorder that could affect the absorption
of CC- 90011.

4. Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly
those with a history of and/or risk of perforation and GI tract hemorrhages.

5. Subject with any hemorrhage/bleeding event > CTCAE Grade 2 or hemoptysis > 1 teaspoon
within 4 weeks prior to the first dose.

6. Subject with symptomatic and untreated or unstable central nervous system (CNS)
metastases.

7. Subject has impaired cardiac function or clinically significant cardiac diseases,
including any of the following:

- Left ventricular ejection fraction (LVEF) 10 mg daily prednisone
equivalent) or other immunosuppressive medications within 30 days of enrollment.
Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily
prednisone equivalent, are permitted in the absence of active autoimmune disease.

• Subjects with type 1 diabetes mellitus, hypothyroidism only requiring hormone
replacement, disorders (such as vitiligo, psoriasis, or alopecia) not requiring
systemic treatment, or conditions not expected to recur in the absence of an external
trigger are permitted to enroll.

22. Subject has received treatment with botanical preparations (eg, herbal supplements or
traditional Chinese medicines) to treat the disease under study within 2 weeks prior
to randomization. Refer to Section 8.2 for prohibited therapies.

23. Subject has history of allergy or hypersensitivity to study drug components.

24. Subject has received a live/attenuated vaccine within 30 days of first treatment.

Contacts and Locations

Contacts

Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations

France
Hospital Le Timone
Marseille Cedex 5

France
CHU Nantes Hopital Nord Laennec
Saint-Herblain

France
Gustave Roussy
Villejuif CEDEX

Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti "Umberto I, G.M. Lancisi, G. Salesi"
Ancona

Italy
Polyclinic S. Orsola-Malpighi
Bologna

Italy
Istituto Clinico Humanitas
Rozzano (MI)

Spain
Vall d´Hebron University Hospital
Barcelona

Spain
Hospital Universitario Germans Trias i Pujol
Barcelona

Spain
Hospital Doce de Octubre
Madrid

Spain
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid

Spain
Hospital Universitario Virgen de la Victoria
Malaga

Spain
Hospital Clinico Universitario de Valencia
Valencia

Spain
Hospital Universitario La Fe
Valencia

Sponsors and Collaborators

Celgene

Investigators

Study Director: Zariana Nikolova, MD, PHD Celgene Corporation

Principal Investigator: Oscar Juan Vidal, MD, PhD Hospital Universitario La Fe

Principal Investigator: Stefania Salvagni, MD Azienda Ospedaliero Universitarua, Policlinico S. Orsola Malpighi

Principal Investigator: Rossana Berardi, MD Ospedali Riuniti di Ancona

Principal Investigator: Armando Santoro, MD IRCCS Instituto Clinic Humanitas

Principal Investigator: Benjamin Besse, MD, PhD Gustave Roussy, Ditep

More Information